A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

Interest in the intraperitoneal delivery of chemotherapy to patients with ovarian cancer with minimal residual disease following initial cytoreductive surgery has been rekindled with the recent ...

“We have run out of chemotherapy options for this patient, so we have referred them for surgical evaluation to see if cytoreductive surgery and HIPEC is an option.” Clearly not all patients with PM ...

CHICAGO — Intraperitoneal (IP) chemotherapy is now an alternative to intravenous (IV) administration that "must be discussed" for women with cytoreduced ovarian cancer, several experts said here at ...

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial This was a multicenter randomized phase ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...

Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...

TAMPA, Fla. — A new study of a cancer treatment called HIPEC, heated intraperitoneal chemotherapy, is showing good results when it comes to treating women with metastatic epithelial ovarian cancer.